$0.15
+0.00 (+3.40%)
Open$0.14
Previous Close$0.14
Day High$0.16
Day Low$0.14
52W High$4.46
52W Low$0.14
Volume—
Avg Volume988.0K
Market Cap13.36M
P/E Ratio—
EPS$-0.89
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+12,812.8% upside
Current
$0.15
$0.15
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 182.66M | 127.92M | 27.35M |
| Net Income | -56,758,535 | -35,774,691 | 6.20M |
| Profit Margin | -31.1% | -29.5% | 22.7% |
| EBITDA | -10,482,012 | -6,973,815 | 9.44M |
| Free Cash Flow | — | — | 4.10M |
| Rev Growth | +42.8% | +42.8% | -0.5% |
| Debt/Equity | 4.00 | 4.00 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.55 | -0.16% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $456.60 | -1.24% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $169.42 | +1.10% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $531.97 | -1.08% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $951.08 | -0.14% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $159.73 | -3.22% | 7.7 | 20.98B |